系统研究新型医学辅助生殖技术终生健康后果的实用蓝图
本文指出生殖医学中多项技术未经充分临床前研究即进入临床,且新型技术可能对子代健康带来风险。作者提出一套基于小鼠模型、涵盖全生命周期的临床前安全性测试蓝图,并敦促科学家在新型生殖技术临床实施前开展所建议的广泛临床前测试,以获取疗效及潜在健康影响的知识,保障新型医学辅助生殖技术的质量。
要点
- 生殖医学中多项技术未经充分临床前研究即被引入临床,IVF首个子代长期健康研究在临床应用十年后才发表。
- 观察性研究提示经医学辅助生殖技术受孕儿童与自然受孕儿童存在差异,但结果常因混杂因素、结局定义不一、评估方案不统一及治疗原因异质性而难以解读。
- 作者提出基于小鼠模型、涵盖全生命周期的临床前安全性测试蓝图,并敦促科学家在新型生殖技术临床实施前开展所建议的广泛临床前测试。
核心结论
- 作者提出一套基于小鼠模型、涵盖全生命周期的临床前测试蓝图,用于评估新型医学辅助生殖技术所生子代的安全性与健康。
- 作者敦促科学家对新型生殖技术开展所建议的广泛临床前测试,以获取疗效及潜在健康影响的知识,保障新型医学辅助生殖技术的质量。
研究设计与样本
- 本文为针对新型医学辅助生殖技术临床前安全性评估框架的论述文章,提出基于小鼠模型、涵盖全生命周期的临床前测试蓝图。
主要发现
- 生殖医学中多项技术未经详尽临床前研究即被临床引入,若开展临床前动物研究则疗效与功能性占主导。
- 新型医学辅助生殖技术被证明有效(即导致活产)后常迅速进入临床;IVF首个子代长期健康研究在临床应用十年后才发表。
- 近年开展的前瞻性随访研究为研究不同生殖技术所生大量儿童的健康提供了机会。
- 此类研究虽提示经医学辅助生殖技术受孕儿童与自然受孕儿童存在差异,但结果常因观察性研究性质(及相关混杂因素风险,如父母生育力低下)、临床结局指标定义差异、评估方案缺乏统一及生育治疗潜在原因异质性而难以解读。
局限性
- 观察性研究存在相关混杂因素风险,如父母生育力低下。
- 临床结局指标定义存在差异。
- 评估方案缺乏统一。
- 生育治疗潜在原因存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In medicine, safety and efficacy are the two pillars on which the implementation of novel treatments rest. To protect the patient from unnecessary or unsafe treatments, usually, a stringent path of (pre) clinical testing is followed before a treatment is introduced into routine patient care. However, in reproductive medicine several techniques have been clinically introduced without elaborate preclinical studies. Moreover, novel reproductive techniques may harbor safety risks not only for the patients undergoing treatment, but also for the offspring conceived through these techniques. If preclinical (animal) studies were performed, efficacy and functionality the upper hand. When a new medically assisted reproduction (MAR) treatment was proven effective (i.e. if it resulted in live birth) the treatment was often rapidly implemented in the clinic. For IVF, the first study on the long-term health of IVF children was published a decade after its clinical implementation. In more recent years, prospective follow-up studies have been conducted that provided the opportunity to study the health of large groups of children derived from different reproductive techniques. Although such studies have indicated differences between children conceived through MAR and children conceived naturally, results are often difficult to interpret due to the observational nature of these studies (and the associated risk of confounding factors, e.g. subfertility of the parents), differences in definitions of clinical outcome measures, lack of uniformity in assessment protocols and heterogeneity of the underlying reasons for fertility treatment. With more novel MARs waiting at the horizon, there is a need for a framework on how to assess safety of novel reproductive techniques in a preclinical (animal) setting before they are clinically implemented. In this article, we provide a blueprint for preclinical testing of safety and health of offspring generated by novel MARs using a mouse model involving an array of tests that comprise the entire lifespan. We urge scientists to perform the proposed extensive preclinical tests for novel reproductive techniques with the goal to acquire knowledge on efficacy and the possible health effects of to-be implemented reproductive techniques to safeguard quality of novel MARs.
引用
- Mulder CL, Serrano JB, Catsburg LAE, et al. A practical blueprint to systematically study life-long health consequences of novel medically assisted reproductive treatments. Hum Reprod. 2018. PMID: 29635479. doi:10.1093/humrep/dey070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。